找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Diagnoses Without Names; Challenges for Medic Michael D. Lockshin,Mary K. Crow,Medha Barbhaiya Book 2022 Springer Nature Switzerland AG 202

[復(fù)制鏈接]
樓主: Clinton
11#
發(fā)表于 2025-3-23 13:25:59 | 只看該作者
Ever-Evolving Disease Classification Criteria for Clinical Trials and Studies: The Case of Systemic ue patient, classification and classification criteria are used to describe populations for clinical trials and studies and to create somewhat homogeneous, reproducible, and understood populations for clinical research. The development of classification criteria with high sensitivity and specificity
12#
發(fā)表于 2025-3-23 16:05:05 | 只看該作者
13#
發(fā)表于 2025-3-23 19:28:52 | 只看該作者
When the Illness Has No Name: Focus on Clinical Trials in Systemic Lupus Erythematosusrials, especially those with oversight by regulatory agencies, are pure, they are not. Systemic lupus erythematosus (SLE) clinical trials suffer from some of the same issues that plague everyday clinical life. Does everyone in a clinical trial truly have SLE? Is the activity score declared in the ca
14#
發(fā)表于 2025-3-23 22:32:15 | 只看該作者
15#
發(fā)表于 2025-3-24 06:16:10 | 只看該作者
Managing and Tolerating Diagnostic Uncertaintyfor managing diagnostic uncertainty, however, this pursuit is inadequate. Diagnostic knowledge takes time to acquire, and diagnostic uncertainty is not completely curable. Furthermore, diagnostic uncertainty elicits negative psychological responses that need to be palliated, as well as positive resp
16#
發(fā)表于 2025-3-24 09:50:41 | 只看該作者
17#
發(fā)表于 2025-3-24 11:21:14 | 只看該作者
In the Box or Out of the Boxtudies in well-defined population. Inclusion and exclusion criteria may be the most important aspect of a clinical study or trial. Lumping or splitting determines which patients can ultimately use a risk stratification algorithm or a therapy. Both processes are valid; studies must be more transparent about how they have lumped or split.
18#
發(fā)表于 2025-3-24 17:54:25 | 只看該作者
19#
發(fā)表于 2025-3-24 21:32:47 | 只看該作者
20#
發(fā)表于 2025-3-25 02:09:14 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 01:19
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
彭州市| 延安市| 宁津县| 若尔盖县| 宁波市| 华蓥市| 商城县| 玉山县| 绥化市| 交城县| 通山县| 尼玛县| 车致| 西昌市| 大同县| 吴忠市| 东明县| 江都市| 大邑县| 出国| 祁东县| 乌鲁木齐县| 会宁县| 长宁县| 蓬莱市| 永登县| 于都县| 华宁县| 交口县| 三门县| 峨眉山市| 顺义区| 天台县| 东至县| 安阳市| 织金县| 札达县| 张家港市| 江山市| 韶山市| 玛多县|